Merck Submits Application for Cladribine Tablets
- Details
- Category: Merck Group
Merck KGaA announced the submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for Cladribine Tablets, Merck's proprietary investigational oral formulation of cladribine, as a therapy for reducing relapses in people with relapsing forms of multiple sclerosis (MS).
The Lilly TB Drug Discovery Initiative Announces New Collaborator
- Details
- Category: Eli Lilly and Company
On behalf of The Lilly TB Drug Discovery Initiative, the Infectious Disease Research Institute (IDRI) signed a Memorandum of Understanding (MOU) with Academia Sinica, a research institution based in Taiwan, to collaborate in target-based screening for the discovery of new tuberculosis (TB) drugs. The Lilly TB Drug Discovery Initiative's most important goal is filling the pipeline for faster, future TB drug development.
Abbott to Acquire Solvay Pharmaceuticals Business
- Details
- Category: Abbott
Abbott today announced a definitive agreement with the Solvay Group for Abbott to acquire Solvay's pharmaceuticals business for EUR 4.5 billion ($6.6 billion) in cash, providing Abbott with a large and complementary portfolio of pharmaceutical products and a significant presence in key global emerging markets.
Novartis bronchodilator QAB149 recommended for approval in European Union
- Details
- Category: Novartis
Novartis has received a positive opinion recommending European Union (EU) approval of QAB149 (indacaterol) for maintenance bronchodilator treatment in adult patients with chronic obstructive pulmonary disease (COPD). When approved, QAB149 and its device, Concept-1, will be known as Onbrez® Breezhaler®[§].
Results from Abbott's PROSPECT Study Provide New Insight
- Details
- Category: Abbott
Abbott (NYSE: ABT) announced primary results from its ground breaking PROSPECT (Providing Regional Observations to Study Predictors of Events in the Coronary Tree) clinical trial. PROSPECT is the first prospective natural history study to evaluate the role of vulnerable plaque in unexpected heart attacks and the natural progression of coronary artery disease.
Herceptin provides impressive survival benefit for patients with high levels of HER2
- Details
- Category: Roche
A detailed analysis of the Phase III ToGA study revealed an unprecedented survival benefit for patients whose tumours exhibited a particularly high level of HER2 when Herceptin (trastuzumab) was added to standard chemotherapy (Xeloda or intravenous 5-FU and cisplatin).
Results of ADAGIO study with Azilect® in Parkinson's disease published
- Details
- Category: Lundbeck
H. Lundbeck A/S' (Lundbeck) partner Teva Phamaceuticals Industries Ltd. (Teva) announced that results from the ADAGIO trial, published online in The New England Journal of Medicine, demonstrated that Parkinson's disease patients receiving Azilect® (rasagiline) 1mg/day at the start of the study (early-start group) experienced superior benefit over 18 months compared with those who started the exact same treatment nine months later (delayed-start group)(1).
More Pharma News ...
- Nexavar® Demonstrates 74 Percent Improvement in Progression-Free Survival
- Analysis of BRAIN study shows that patients may have a stabilisation or improvement
- Denosumab Demonstrates Superiority Over Zometa(R)
- Pfizer and Wyeth to Divest Certain Animal Health Assets to Boehringer Ingelheim
- Bayer Announces New Data on Oncology Portfolio To Be Presented at the ECCO-ESMO Congress 2009
- Bayer Announces New Data on Oncology Portfolio To Be Presented at the ECCO-ESMO Congress
- U.S. FDA Licenses Sanofi Pasteur's Pandemic Influenza Vaccine